SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), commonly known as flozins, are drugs developed in the last decade for glycemic control in the type 2 diabetes mellitus (T2D) population that have consistently proven a positive effect on adverse cardiovascular and renal outcomes (11–13).